FRONTIER SCIENCE | PUBLICATIONS

NeoALTTO: European Journal of Cancer (EJC)

Title of Publication

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

AUTHORS

Paolo Nuciforo; John Townend; Martine J. Piccart; Shona Fielding; Panagiota Gkolfi, Sarra El-Abed; Evandro de Azambuja; Gustavo Werutsky; Judith Bliss; Volker Moebus; Marco Colleoni; Alvaro Moerno Aspitia; Henry Gomez; Andrea Gombos; Maria A. Coccia-Portugal; Ling-Ming Tseng; Georg Kunz; Guillermo Lerzo; Joohyuk Sohn; Vladimir Semiglazov; Cristina Saura; Judith Kroep; Antonella Ferro; David Cameron; Richard Gelber; Jens Huober; Serena Di Cosimo

Publication Reference

European Journal of Cancer (EJC) | Volume 181 | Issue | Page(s) 92-101 | Publication Year 2023

 

READ FULL PUBLICATION

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more
APHINITY | European Journal of Cancer (EJC)

APHINITY | European Journal of Cancer (EJC)

Mar 18, 2022

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

read more
APHINITY | AACR Cancer Research

APHINITY | AACR Cancer Research

Feb 15, 2022

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.

read more